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ABSTRACT
Introduction: Cryoablation is an acceptable treatment option
for small renal cortical neoplasms (RCN). Unlike extirpative
interventions, intraoperative needle biopsy is the only patho-
logic data for ablated tumors. It is imperative that sampled tissue
accurately captures pathology. We studied the optimal intraop-
erative needle core biopsy protocol for small RCN during lapa-
roscopic renal cryoablation (LCA).
Methods: Patients with RCN4cm underwent intraoper-
ative biopsy during LCA. Four biopsy cores were taken
per tumor, 2 before and 2 after LCA by using both a
standard and modified technique. Standard technique:
needle biopsy device was deployed after insertion into the
renal tissue at a depth of 5mm. Modified technique: nee-
dle biopsy device was deployed 1mm outside of the renal
tissue. Biopsies were examined and compared with refer-
ence standard pathology. Percentage agreement was cal-
culated across biopsy types (standard vs. modified) and
time points (pre- vs. postcryoablation). Logistic regression
was used to identify factors impacting biopsy accuracy.
Results: Thirty patients with 33 RCNs underwent LCA.
The mean patient age was 69.18.0yrs, and mean tumor
size was 2.30.7cm. No significant bleeding resulted from
biopsies. A definitive diagnosis was made in 31/33 RCNs
(94.0%). Ten tumors (30.3%) were benign, 21 (63.7%)
were malignant, and 2 (6.0%) were nondiagnostic. Biopsy
length was significantly longer using the standard vs.
modified technique with mean lengths of 9.3mm vs.
7.0mm, respectively (P.02). Highest agreement was seen
in preablation biopsies (90.3%). A significant association
with agreement was seen for younger age (P.05) and
larger tumor size (P.02).
Conclusions: Younger age and larger tumor size were
associated with improved accuracy. Preoperative sam-
pling resulted in superior accuracy and the standard tech-
nique resulted in significantly longer cores. Use of preab-
lation standard biopsy technique may result in the most
accurate pathologic diagnosis for patients undergoing
cryoablation for small RCNs.
Key Words: Renal cell carcinoma, Renal cryoablation,
Needle core biopsy, Renal pathology.
INTRODUCTION
In contemporary clinical practice, preoperative renal bi-
opsy is not routinely performed to guide treatment deci-
sions for contrast enhancing renal cortical neoplasms
(RCNs). It is well known that 80% to 90% of all enhancing
RCNs are malignant in nature with reported rates of be-
nign disease of surgically treated masses ranging from
6.1% to 16.9%.1–3 Pathologic evaluation of renal masses
demonstrates significant differences in oncologic out-
comes, including progression to distant metastasis and
cancer-specific death based on the Heidelberg histological
subtype.4 Following extirpation, the pathologic evaluation
of tissue provides valuable information about the stage of
the malignancy and the patient’s prognosis in terms of
cancer recurrence and survival. For ablative techniques,
postoperative tissue evaluation is limited to core needle
biopsy or aspiration taken at the time of surgery. This
information can be helpful, because up to a third of RCNs
(4.0cm) are benign.5 Given that needle biopsy at the
time of surgery is often the only pathologic data for tu-
mors treated with ablation, it is imperative that the sam-
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SCIENTIFIC PAPERpled tissue accurately captures the true underlying tumor
histopathology. A meta-analysis of 47 series of cryoabla-
tion and RFA procedures for RCNs revealed that only
82.3% of cryoablation cases and 62.2% of RFA cases un-
derwent preablation biopsy.6 Of the RCNs that were bi-
opsied, 33.5% had unknown or indeterminate pathology
highlighting the high rate of intraoperative biopsy failure
for ablative modalities.
Side effects from preoperative renal biopsy are rare but
include a 1% to 2% risk of hemorrhage, infection, and a
0.01% risk of tumor seeding along the needle tract.7–10
Ideally, an intraoperative biopsy protocol would optimize
histopathologic accuracy and minimize side effects asso-
ciated with the procedure. In a porcine pilot study, we
demonstrated the feasibility of a postablative biopsy
protocol in an effort to optimize the oncologic safety
and address the concern with tumor seeding, which has
served as a real barrier for many clinicians, preventing
the universal practice of intraoperative biopsies of
RCNs.11 Theoretically, postablation biopsy should re-
duce the risk of tumor seeding, given that the tissue in
question would not be viable prior to extraction
through the needle tracts. In addition, a second pilot
study in our laboratory compared the accuracy of 2
different biopsy techniques at detecting renal tumor
architecture during cryoablation and concluded that a
modified technique (Figure 1)12 was as equally safe and
feasible as the currently used standard technique.13 The
modified technique was developed with the hope that the
longer time for the biopsy needle to accelerate outside the
renal parenchyma may result in sharper cuts and cleaner
biopsy specimens. In the current study, we compared 2
core needle biopsy techniques taken before and after
renal cryoablation. The main objective of this study was to
identify the biopsy protocol associated with the highest
level of accuracy for identifying tumor histopathology in
patients undergoing LCA for small RCNs. By identifying
the ideal biopsy protocol, we hope to improve upon the
low intraoperative biopsy rate and the high biopsy failure
rate for ablative treatments of RCNs.6
MATERIALS AND METHODS
Patients
This prospective study was conducted under the review
and approval of our institutional review board. Between
July 2007 and February 2009, 30 consecutive patients with
solid, enhancing RCNs 4cm in diameter underwent in-
traoperative tumor biopsy during standard LCA by a single
surgeon (JL). All enrolled subjects signed an IRB-ap-
proved consent form and underwent LCA via either a
retroperitoneal or transperitoneal approach.
Procedure
Following mobilization of the affected kidney, the loca-
tion of the tumor was identified and confirmed using a
standard laparoscopic ultrasound system (SUS) (BK Med-
ical Systems Inc, Peabody, MA). Once identified, an 18-
gauge biopsy needle (Bard MaxCore, Covington, GA) was
used to sample (preablation biopsy) the renal mass prior
to placement of the icerods (Galil Medical Inc., Arden
Hills, MN). A total of 2 cores were taken, one using a
standard and one using a modified technique as previ-
ously described and illustrated in Figure 1.12 In the stan-
dard technique, the needle biopsy device was deployed
after insertion into the renal tissue under ultrasound guid-
ance at a depth of 5mm. In the modified technique, the
needle biopsy device was deployed 1mm outside of the
renal tissue. For exophytic lesions, the biopsy needle was
guided to the lesion under direct vision. For endophytic
Figure 1. Biopsy Techniques.14 Image A and B depict the Mod-
ified Technique in which the biopsy needle is placed at a depth
of 5mm in the renal parenchyma (A) prior to sampling (B).
Image C and D depict the Standard Technique in which the
biopsy needle is held 1mm outside the renal parenchyma (C)
prior to sampling (D).
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dle placement. A standard double freeze-thaw cycle was
used as previously described to adequately ablate the in-
volved tissue.14 Procedures were performed using a com-
mercially available cryoablation machine (SeedNet Gold)
(Galil Medical Inc., Arden Hills, MN) and utilized a variable
number of 1.47-mm cryoablation probes (IceRods. Galil
Medical Inc., Arden Hills, MN). Complete ablation was con-
firmed using SUS to measure the size and extent of the ice
ball formation. Once the tissue was fully thawed and the
icerods had been removed, 2 postablation core needle
biopsy specimens (standard and modified) were taken
under ultrasound guidance utilizing the identical protocol
performed preoperatively.
Information was recorded for each patient including age,
race, tumor size, location (exophytic/endophytic/meso-
phytic), biopsy core length, and specimen histology. We
classified lesions based on the percentage of tumor that
extends beyond the normal renal parenchymal contour;
exophytic tumors have 60% of their mass outside the
natural contour of the kidney. Endophytic tumors have
60% of their mass within the natural border of the
kidney, and mesophytic tumors have 40% to 60% of their
mass in either direction.13
Biopsy Processing
All 4 biopsy cores were separately labeled in containers
and then fixed in 5% formalin solution, placed in cassettes,
and embedded in paraffin. Each cassette was then sec-
tioned 3 times and stained using hematoxylin and eosin.
Physical characteristics of each biopsy specimen were
obtained, including gross measurements of the core
lengths as well as a pathologic description of the tumor
architecture. Each biopsy core was evaluated by 1 of 2
dedicated urologic pathologists (LH or KMO) who were
blinded to the nature of the biopsy technique used and
whether the biopsy was pre- or postcryoablation. A final
pathologic description/diagnosis of each biopsy specimen
was recorded.
Biopsies were classified as malignant, benign, or nondi-
agnostic based on the interpretation of the uropathologist.
Malignant tumors were classified per the Heidelberg clas-
sification system.15 Benign tumors included oncocytoma,
angiomyolipoma, metanephric adenoma, or a renal cyst.
Nondiagnostic biopsies were identified if only normal
renal parenchyma or fibrosis was present, preventing a
definitive diagnosis.
Statistical Methods
The reference standard histopathology was determined
for each tumor by taking the maximum (ie, highest grade)
tumor pattern across all 4 biopsy specimens. Therefore, if
one biopsy was classified as malignant and the remaining
3 were benign, the reference standard was deemed ma-
lignant. Further, if one biopsy was classified as benign and
the remaining were nondiagnostic, the reference standard
was deemed benign. In cases in which all 4 biopsies were
termed nondiagnostic, no true diagnosis was given. Be-
cause no reference standard could be determined, these
patients were subsequently removed from the analysis of
biopsy agreement.
The accuracy of biopsies to identify the reference standard
cell type histopathology (not grade) was evaluated using
agreement scores or percentage of biopsies in agreement
with the reference standard pathology. Agreement was
defined as an individual biopsy resulting in the identical
cell type histopathologic diagnosis as the reference stan-
dard for the RCN. Cohen’s kappa was used as a measure
of agreement between reference standard pathology for
each individual biopsy. A kappa coefficient up to 0.20 was
considered as a slight agreement, between 0.21 and 0.40
as a fair agreement, between 0.41 and 0.60 as a moderate
agreement, between 0.61 and 0.80 as a substantial agree-
ment, and 0.80 as an almost perfect agreement.16
Logistic regression was used to evaluate the impact of
biopsy length, age, race, tumor size, and tumor location
on biopsy agreement. This calculation reflected the fact
that 4 biopsies from each patient shared repeated vari-
ables, including age, race, tumor size, and tumor location
through repeated measure analysis. Finally, biopsy length
was compared across all biopsy types using a Wilcoxon
rank sum test. The threshold for significance was set at
P.05.
RESULTS
Thirty patients with 33 renal tumors underwent LCA. Pa-
tient demographic information is summarized in Table 1.
The mean patient age was 69.18.0 years with a mean
tumor size of 2.30.7cm (range, 0.5 to 3.8). One (3%)
patient was Asian, 5 (15%) were African American, 1 (3%)
was Hispanic, 22 (67%) were Caucasian, and 4 (12%)
selected “other” as their race. Sixteen (49%) of the tumors
were classified as endophytic, 14 (42%) were exophytic,
and 3 (9%) were mesophytic. The mean estimated blood
loss for all procedures was 72.6103.5mL (range, 5 to
300).
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atively under SUS guidance with 33 occurring preablation
with the standard method, 33 occurring preablation with
the modified method, 26 occurring postablation with the
standard method, and 26 occurring postablation with the
modified method. No significant intraoperative bleeding
resulted from any of the biopsies taken. Overall, when all
biopsies were included, a definitive diagnosis was made
in 31 of the 33 renal tumors (94.0%). Of the 31 lesions in
which a pathologic diagnosis was made, 10 (32.2%) were
designated as benign RCNs with the remaining 21 (67.7%)
described as malignant. Table 2 details the breakdown of
pathologic diagnoses given for all patients.
Across all samples, biopsy length was significantly lon-
ger using the standard technique compared to the mod-
ified technique with mean lengths of 9.35.9mm vs.
7.04.6mm, respectively (P.02). No significant differ-
ence in length was seen when comparing biopsy length
for all preablation vs. postablation samples with mean
lengths of 8.85.8mm vs. 7.34.8mm, respectively
(P.2) (Figure 2).
Table 3 summarizes the percentage (%) agreement and
kappa score for each biopsy type with the pathologic
reference standard diagnosis. The highest agreement was
seen in preablation biopsies using both the standard and
modified approach, 90.3% each. Following logistic regres-
sion analysis (Table 4), significant association with agree-
ment was seen for age (P.05) and tumor size (P.02).
No significant association was seen for biopsy length
(P.09), race (P.4), or tumor location (exophytic, P.2/
endophytic, P.6). When controlling for race, biopsy size,
tumor size, and tumor location, percentage agreement
with reference standard histopathology decreased as age
increased (P.05). When controlling for age, race, biopsy
size, and tumor location, percentage agreement with ref-
erence standard histopathology increased as tumor size
increased (P.02).
DISCUSSION
In standard practice, biopsies taken during renal ablation
procedures are typically performed prior to the ablative in-
tervention. While there is little clinical evidence for tumor
seeding during cryoablation procedures, some urologists
have been hesitant to biopsy renal tumors at the time of the
procedure. In 2004, Margulis and colleagues17 reported that
post-RFA biopsy is sufficient for accurate pathologic diagno-
sis. Postablation biopsy will theoretically reduce the risk of
tumor seeding, given that the tissue in question would not be




Mean Patient Age (years) 69.18.0
Mean Tumor Size (diameter in cm) 2.30.7
Race (%)
Asian 1 (3)








Estimated Blood Loss (mL) 72.6103.5
Table 2.
Histopathology After Renal Core Biopsy
Biopsy Result Pathology # of tumors % of tumors
Malignant Clear Cell Renal Carcinoma 12 36.4 63.7
Papillary Renal Carcinoma 6 18.2
Chromophobe Renal Carcinoma 3 9.1
Benign Oncocytoma 9 27.3 30.3
Angiomyolipoma 1 3.0
Nondiagnostic Normal Renal Parenchyma 1 3.0 6.0
Scant Fibrous Tissue 1 3.0
Total 33 100
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distinctly different ablation mechanisms, we previously eval-
uated and demonstrated the feasibility of postcryoablation
biopsy in the porcine setting.11
In recent years, advancements in renal biopsy technol-
ogy and pathologic analysis have led to improvements
in the accuracy of distinguishing benign from malignant
tumors.18 Studies comparing renal biopsy results with
pathologic evaluation of nephrectomy specimens re-
port average concordance rates of 92% to 95%7,9,19 up
from an average rate of 88.9% before 2001.18 Further-
more, a metaanalysis across all renal mass biopsy stud-
ies reported mean sensitivity and specificity of 92.1%
and 89.7%, respectively.18 Across all renal biopsies, our
Figure 2. Box-plot of biopsy lengths (mm) (pre- vs. postablation and standard vs. modified technique).
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pathology was 94%, which parallels results from con-
temporary renal biopsy studies. Previously, we evalu-
ated the histologic accuracy of needle core biopsy
before and after renal cryoablation.11 Diagnostic accu-
racy of both pre- and postcryoablation sampling was
70%. In a separate pilot evaluation, we evaluated the
accuracy of 2 different biopsy techniques (standard vs.
modified) at determining tumor histopathology during
renal cryoablation.12 The biopsy techniques studied are
illustrated in Figure 1. The pilot study revealed that the
standard and modified techniques established a diag-
nosis in 7 of 10 and 9 of 10 cases, respectively.12
In our study, a diagnosis could not be made in 2 (6%) of
the patients. False-negative results are usually due to sam-
pling error, which can include sampling of necrotic tissue,
normal renal parenchyma, or an insufficient amount of
tissue. Previous studies report false-negative rates due to
technical limitations or insufficient tissue sampling rang-
ing from 0% to 30%,9 which is slightly higher than our
reported failure rate. Finally, contemporary studies docu-
ment that up to 40% of all RCNs are benign, which is
consistent with our pathologic results and confirms that
our sample accurately reflects the general popula-
tion.5,20–22
Results from this study indicate that factors associated with
improved pathologic accuracy of the renal biopsy include
a younger patient age and larger tumor size. It should be
noted that all patients in the current study had T1a (4cm)
renal masses, and the term “larger” must be taken in this
context. Previous studies demonstrate that biopsy failure
rates are higher for smaller renal tumors.23 A study by
Lechevallier and coworkers23 found that biopsy failure
rates were as high as 37% for tumors 3cm compared
with 9% for tumors 3cm. This observation is intuitive,
because there is a greater chance of miss-sampling the
Table 3.
Percentage Agreement and Kappa Score by Biopsy Type
Biopsy Type % Agreement with
Reference Standard
Kappa SE P-Value % Nondiagnostic
Specimens
Preablation Standard 90.3 (28/31) 0.81 0.15 .0001 15.2 (5/33)
Preablation Modified 90.3 (28/31) 0.81 0.15 .0001 15.2 (5/33)
Postablation Standard 41.7 (10/24) 0.25 0.08 .0007 61.5 (16/26)
Postablation Modified 37.5 (9/24) 0.21 0.07 .002 65.4 (17/26)
Column 1 details the percentage agreement with the reference standard pathology for each individual biopsy. For this calculation, only
RCNs with a definitive diagnosis (n31 for preablation biopsies and n24 for postablation biopsies) were included as described in the
Methods. In addition, kappa score with standard error and P-values are listed. Column 3 details the overall percentage of nondiagnostic
specimens across all biopsies taken (n33 for preablation biopsies and n26 for postablation biopsies).
Table 4.
Analysis of Empirical Standard Error Estimates for Logistic Regression Analysis of Repeated Measures
Parameter Estimate Standard Error 95% Confidence
Limits
ZP r  Z
Biopsy Length 0.0838 0.0499 0.0140 0.1815 1.68 0.09
Age 0.0645 0.0323 0.1279 0.0011 1.99 0.05
Race Other 0.1309 0.8060 1.7107 1.4490 0.16 0.87
Hispanic 0.5686 0.4696 1.4891 0.3518 1.21 0.2
White 0.5024 0.6063 1.6908 0.6860 0.83 0.4
Asian 1.7447 0.9076 3.5236 0.0341 1.92 0.06
Tumor Size 0.1123 0.0468 0.0206 0.2039 2.40 0.02
Tumor Location Exophytic 1.2134 0.8612 2.9014 0.4746 1.41 0.2
Endophytic 0.5256 0.9503 2.3882 1.3371 0.55 0.6
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not consistently found in all renal biopsy studies. A recent
study by Wang and Wood24 demonstrated that of 110
small RCN biopsies 4cm, no difference was found in
terms of diagnostic accuracy as a function of tumor size.
Regardless, improvements in image-guided biopsy tech-
niques should continue to reduce this sampling error by
enhancing the ability of real-time tumor identification.
Such results suggest that more aggressive biopsy proto-
cols for those patients at greatest risk for biopsy failure,
(older patients with smaller tumors) may improve sam-
pling accuracy.
Diagnostic accuracy in our study was vastly superior for
the preablation samples compared to those taken postab-
lation with percentage accuracies of 90% vs. approxi-
mately 40%. Furthermore, the percentage of nondiagnos-
tic samples was much greater for the postablation biopsies
with rates 60% vs. only 15% in the preablation samples.
No major difference in accuracy was seen for biopsy
technique (standard vs. modified). These results contra-
dict the findings of our previous pilot study, which found
no difference in diagnostic accuracy for samples taken
pre- vs. postcryoablation (70% for both).11 A likely expla-
nation for this discrepancy is the very small sample size of
our pilot study, which was likely insufficient to detect a
significant difference across sampling time points.
When interpreting these findings, it is important to con-
sider that the artifact created by the ablative process and
the preablation biopsy procedure confound the results.
Such an artifact likely impacted the quality of the postab-
lation specimens and may partially explain the differential
results. With the current data, it is certainly reasonable to
perform only postablation biopsies if the surgeon is con-
cerned about tumor seeding. However, the diminished
results from postcryoablation biopsy should be taken into
consideration in this setting.
Although no difference in the diagnostic accuracy of sam-
ples taken via the standard or modified technique was
seen, our results show that the standard technique results
in significantly longer samples. This is highly intuitive,
because the modified technique does not allow for full
excursion of the biopsy mechanism into the tumor. There
are also limitations to the modified technique. Specifically,
lesions that are completely endophytic may not be acces-
sible via the modified technique, because the depth of
penetration is limited. Given the small differences in di-
agnostic accuracy across biopsy techniques, no statement
of superiority can be made. However, given the improved
biopsy length and the possible limitations of the modified
technique, it is our recommendation that the standard
technique remains the gold standard at this time.
The diagnostic accuracy for individual biopsies ranged
from only 37.5% to 90.3%; however, when combined
together, the accuracy improved to 94.0%. Results from
our prior study also supported this finding, demonstrating
an improvement from 70% to 90% for individual biopsies
to 100% when combining results of all biopsies.12 In-
creased accuracy of identifying “true” pathology with
greater number of biopsies has been illustrated in previ-
ous studies of renal tumors25 and is well established in
prostate cancer.26 The greater number of biopsies likely
increases the chance of sampling the affected tissue. Al-
though it would seem that a greater number of biopsies
should result in increased risk of bleeding, studies to date
have not shown this to be true for fine needle biopsies of
renal tumors.19
An important limitation of our study is that no third party
reference standard was used to make a definitive patho-
logic diagnosis of the renal tumor. Because there is no
postoperative extirpative sample in cryoablation, only the
biopsy specimens can be used to make the final diagnosis.
Furthermore, although each biopsy was treated as an
independent measure, the repeated measures across bi-
opsies per tumor (ie, patient age, tumor location, tumor
size, and race) introduced confounders into our analysis.
Although we tried to control for this statistically using the
generalized estimating equation, it is impossible to com-
pletely remove this effect from the final results. In addi-
tion, postablation biopsies may have been impacted by
mechanical artifacts introduced by preablation biopsies,
and no randomization protocol was used to control for
this effect.
CONCLUSION
This prospective study confirms the diagnostic accuracy of
intraoperative renal tumor needle core biopsy for patients
undergoing cryoablation for RCNs. Factors associated
with improved diagnostic accuracy include younger age
and larger tumor size. Preablation sampling results in
superior diagnostic accuracy, and the standard biopsy
technique results in significantly longer biopsy cores. Use
of a preablation standard biopsy technique results in the
most accurate pathologic diagnosis for patients undergo-
ing cryoablation for RCNs.
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